|
1
|
Li Z, Zhu W, Xiong L, Yu X, Chen X and Lin
Q: Role of high expression levels of STK39 in the growth, migration
and invasion of non-small cell type lung cancer cells. Oncotarget.
7:61366–61377. 2016.PubMed/NCBI
|
|
2
|
Bernatsky S, Ramsey-Goldman R, Petri M,
Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG,
Peschken C, et al: Smoking is the most significant modifiable lung
cancer risk factor in systemic lupus erythematosus. J Rheumatol.
45:393–396. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan J, Zhang W, Lei C, Qiao B, Liu Q, Chen
Q, Jiao H, Jiang L, Cui S and Chen J: Vascular endothelial growth
factor polymorphisms and lung cancer risk. Int J Clin Exp Med.
8:6406–6411. 2015.PubMed/NCBI
|
|
4
|
Feng X, Qin JJ, Zheng BS, Huang LL, Xie XY
and Zhou HF: Association of epidermal growth factor receptor (EGFR)
gene polymorphism with lung cancer risk: A systematic review. J
Recept Signal Transduct Res. 34:333–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Higashi K, Ueda Y, Arisaka Y, Sakuma T,
Nambu Y, Oguchi M, Seki H, Taki S, Tonami H and Yamamoto I: 18F-FDG
uptake as a biologic prognostic factor for recurrence in patients
with surgically resected non-small cell lung cancer. J Nucl Med.
43:39–45. 2002.PubMed/NCBI
|
|
6
|
Wang J, Sheng Z, Yang W and Cai Y:
Elevated serum concentration of chitinase 3-like 1 is an
independent prognostic biomarker for poor survival in lung cancer
patients. Cell Physiol Biochem. 38:461–468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Li H, Han J and Zhang Y:
Down-regulation of microRNA-124 is correlated with tumor metastasis
and poor prognosis in patients with lung cancer. Int J Clin Exp
Pathol. 8:1967–1972. 2015.PubMed/NCBI
|
|
8
|
Hou J, Meng F, Chan LW, Cho WC and Wong
SC: Circulating plasma MicroRNAs as diagnostic markers for NSCLC.
Front Genet. 7:1932016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kuribayashi K, Funaguchi N and Nakano T:
Chemotherapy for advanced non-small cell lung cancer with a focus
on squamous cell carcinoma. J Cancer Res Ther. 12:528–534. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Costa DF and Torchilin VP: Micelle-like
nanoparticles as siRNA and miRNA carriers for cancer therapy.
Biomed Microdevices. 20:592018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marwitz S, Heinbockel L, Scheufele S,
Kugler C, Reck M, Rabe KF, Perner S, Goldmann T and Ammerpohl O:
Fountain of youth for squamous cell carcinomas? On the epigenetic
age of non-small cell lung cancer and corresponding tumor-free lung
tissues. Int J Cancer. 143:3061–3070. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng CH, Chen XM, Zhang FB, Zhao C and Tu
SS: Inhibition of CXCR4 regulates epithelial mesenchymal transition
of NSCLC via the Hippo-YAP signaling pathway. Cell Biol Int.
42:1386–1394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi Y, Sakaguchi K, Horio H,
Hiramatsu K, Moriya S, Takahashi K and Kawakita M: Urinary N1,
N12-diacetylspermine is a non-invasive marker for the diagnosis and
prognosis of non-small-cell lung cancer. Br J Cancer.
113:1493–1501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo C, Tetteh PW, Merz PR, Dickes E,
Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek
B, Schadendorf D, et al: miR-137 inhibits the invasion of melanoma
cells through downregulation of multiple oncogenic target genes. J
Invest Dermatol. 133:768–775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jing XG, Chen TF, Huang C, Wang H, An L,
Cheng Z and Zhang GJ: MiR-15a expression analysis in non-small cell
lung cancer A549 cells under local hypoxia microenvironment. Eur
Rev Med Pharmacol Sci. 21:2069–2074. 2017.PubMed/NCBI
|
|
16
|
Ning T, Peng Z, Li S, Qu Y, Zhang H, Duan
J, Wang X, Yang H, Liu R, Deng T, et al: miR-455 inhibits cell
proliferation and migration via negative regulation of EGFR in
human gastric cancer. Oncol Rep. 38:175–182. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ning T, Zhang H, Wang X, Li S, Zhang L,
Deng T, Zhou L, Liu R, Wang X, Bai M, et al: miR-370 regulates cell
proliferation and migration by targeting EGFR in gastric cancer.
Oncol Rep. 38:384–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshino H, Yonemori M, Miyamoto K,
Tatarano S, Kofuji S, Nohata N, Nakagawa M and Enokida H:
microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis
through revival of TWIST1 in renal cell carcinoma. Oncotarget.
8:20881–20894. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Mai Q and Chen J: MicroRNA-210 is
increased and it is required for dedifferentiation of osteosarcoma
cell line. Cell Biol Int. 41:267–275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu D, Xia H, Wang F, Chen C and Long J:
MicroRNA-210 interacts with FBXO31 to regulate cancer proliferation
cell cycle and migration in human breast cancer. Onco Targets Ther.
9:5245–5255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eilertsen M, Andersen S, Al-Saad S,
Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT
and Bremnes RM: Positive prognostic impact of miR-210 in non-small
cell lung cancer. Lung Cancer. 83:272–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Puisségur MP, Mazure NM, Bertero T,
Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K,
Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late
stages of lung cancer and mediates mitochondrial alterations
associated with modulation of HIF-1 activity. Cell Death Differ.
18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H,
Liu X, Le H and Zhang Y: Diagnostic value of serum miR-182,
miR-183, miR-210, and miR-126 levels in patients with early-stage
non-small cell lung cancer. PLoS One. 11:e01530462016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
26
|
Takikawa T, Masamune A, Hamada S, Nakano
E, Yoshida N and Shimosegawa T: miR-210 regulates the interaction
between pancreatic cancer cells and stellate cells. Biochem Biophys
Res Commun. 437:433–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Q, Xu C, Yuan W, Wang C, Zhao P, Chen L
and Ma J: Evaluation of plasma MicroRNAs as diagnostic and
prognostic biomarkers in pancreatic adenocarcinoma: miR-196a and
miR-210 could be negative and positive prognostic markers,
respectively. Biomed Res Int 2017. 64958672017.
|
|
28
|
Qu A, Du L, Yang Y, Liu H, Li J, Wang L,
Liu Y, Dong Z, Zhang X, Jiang X, et al: Hypoxia-inducible MiR-210
is an independent prognostic factor and contributes to metastasis
in colorectal cancer. PLoS One. 9:e909522014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang W, Qu A, Liu W, Liu Y, Zheng G, Du L,
Zhang X, Yang Y, Wang C and Chen X: Circulating miR-210 as a
diagnostic and prognostic biomarker for colorectal cancer. Eur J
Cancer Care (Engl). 26:2017. View Article : Google Scholar
|
|
30
|
Bar I, Merhi A, Abdel-Sater F, Ben Addi A,
Sollennita S, Canon JL and Delrée P: The MicroRNA miR-210 is
expressed by cancer cells but also by the tumor microenvironment in
triple-negative breast cancer. J Histochem Cytochem. 65:335–346.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shidfar A, Costa FF, Scholtens D, Bischof
JM, Sullivan ME, Ivancic DZ, Vanin EF, Soares MB, Wang J and Khan
SA: Expression of miR-18a and miR-210 in normal breast tissue as
candidate biomarkers of breast cancer risk. Cancer Prev Res
(Phila). 10:89–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J
and Zhang S: High expression levels of miR-21 and miR-210 predict
unfavorable survival in breast cancer: a systemic review and
meta-analysis. Int J Biol Markers. 30:e347–e358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fedorko M, Stanik M, Iliev R,
Redova-Lojova M, Machackova T, Svoboda M, Pacik D, Dolezel J and
Slaby O: Combination of MiR-378 and MiR-210 serum levels enables
sensitive detection of renal cell carcinoma. Int J Mol Sci.
16:23382–23389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Redova M, Poprach A, Besse A, Iliev R,
Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R
and Slaby O: MiR-210 expression in tumor tissue and in vitro
effects of its silencing in renal cell carcinoma. Tumour Biol.
34:481–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samaan S, Khella HW, Girgis A, Scorilas A,
Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-said H
and Yousef GM: miR-210 is a prognostic marker in clear cell renal
cell carcinoma. J Mol Diagn. 17:136–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang H, Mao F, Shen T, Luo Q, Ding Z,
Qian L and Huang J: Plasma miR-145, miR-20a, miR-21 and miR-223 as
novel biomarkers for screening early-stage non-small cell lung
cancer. Oncol Lett. 13:669–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB
and Shao GG: Prognostic significance of serum microRNA-210 levels
in nonsmall-cell lung cancer. J Int Med Res. 41:1437–1444. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bansal N, Bosch A, Leibovitch B, Pereira
L, Cubedo E, Yu J, Pierzchalski K, Jones JW, Fishel M, Kane M, et
al: Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and
confers retinoid sensitivity in triple negative breast cancer.
Oncotarget. 7:43689–43702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lewis MJ, Liu J, Libby EF, Lee M, Crawford
NP and Hurst DR: SIN3A and SIN3B differentially regulate breast
cancer metastasis. Oncotarget. 7:78713–78725. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Solaimani P, Wang F and Hankinson O:
SIN3A, generally regarded as a transcriptional repressor, is
required for induction of gene transcription by the aryl
hydrocarbon receptor. J Biol Chem. 289:33655–33662. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Suzuki H, Ouchida M, Yamamoto H, Yano M,
Toyooka S, Aoe M, Shimizu N, Date H and Shimizu K: Decreased
expression of the SIN3A gene, a candidate tumor suppressor located
at the prevalent allelic loss region 15q23 in non-small cell lung
cancer. Lung Cancer. 59:24–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Das TK, Sangodkar J, Negre N, Narla G and
Cagan RL: Sin3a acts through a multi-gene module to regulate
invasion in Drosophila and human tumors. Oncogene. 32:3184–3197.
2013. View Article : Google Scholar : PubMed/NCBI
|
